Drugs for bad bugs: confronting the challenges of antibacterial discovery

被引：1947

作者：

Payne, David J. ^{[1
]}

Gwynn, Michael N. ^{[1
]}

Holmes, David J. ^{[1
]}

Pompliano, David L. ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Infect Dis Ctr Excellence Drug Discovery, Collegeville, PA 19426 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2007年 / 6卷 / 01期

关键词：

D O I：

10.1038/nrd2201

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.

引用

页码：29 / 40

页数：12

共 34 条

[1] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[2]

Aubart K, 2006, PROGR MED CHEM, V44, P109, DOI 10.1016/S0079-6468(05)44403-3

[3] Antibiotic discovery: is it all in the genes? [J].

Brown, JR ;

Warren, PV .

DRUG DISCOVERY TODAY, 1998, 3 (12) :564-566

[4]

CHAN P, 2002, CURR DRUG TARGETS IN, V2, P109

[5]

Chan P.F., 2004, DRUG DISCOV TODAY TH, V1, P519, DOI DOI 10.1016/J.DDSTR.2004.11.003

[6] Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae [J].

Chan, PF ;

O'Dwyer, KM ;

Palmer, LM ;

Ambrad, JD ;

Ingraham, KA ;

So, C ;

Lonetto, MA ;

Biswas, S ;

Rosenberg, M ;

Holmes, DJ ;

Zalacain, M .

JOURNAL OF BACTERIOLOGY, 2003, 185 (06) :2051-2058

[7] An array of target-specific screening strains for antibacterial discovery [J].

DeVito, JA ;

Mills, JA ;

Liu, VG ;

Agarwal, A ;

Sizemore, CF ;

Yao, ZJ ;

Stoughton, DM ;

Cappiello, MG ;

Barbosa, MDFS ;

Foster, LA ;

Pompliano, DL .

NATURE BIOTECHNOLOGY, 2002, 20 (05) :478-483

[8] Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria [J].

Du, WS ;

Brown, JR ;

Sylvester, DR ;

Huang, JZ ;

Chalker, AF ;

So, CY ;

Holmes, DJ ;

Payne, DJ ;

Wallis, NG .

JOURNAL OF BACTERIOLOGY, 2000, 182 (15) :4146-4152

[9] Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus [J].

Fan, F ;

Yan, K ;

Wallis, NG ;

Reed, S ;

Moore, TD ;

Rittenhouse, SF ;

DeWolf, WE ;

Huang, JZ ;

McDevitt, D ;

Miller, WH ;

Seefeld, MA ;

Newlander, KA ;

Jakas, DR ;

Head, MS ;

Payne, DJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3343-3347

[10] Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry [J].

Feher, M ;

Schmidt, JM .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (01) :218-227

← 1 2 3 4 →